Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical…
Biotechnology
US, Pittsburgh [HQ]
Ratios
8 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross Margin | - - | - - | 100.00 | - - | - - | - - | - - | 84.02 | |
| Profit Margin | - - | - - | -1,060.27 | - - | - - | - - | - - | 21.56 | |
| Operating Margin | - - | - - | -1,160.27 | - - | - - | - - | - - | -191.77 | |
|
EPS Growth
|
- - | -448.15 | 34.46 | -23.71 | -42.50 | -83.04 | -75.40 | 107.29 | |
| EPS USD | -27.00 | -148.00 | -97.00 | -120.00 | -171.00 | -313.00 | -549.00 | 40.00 | |
| Return on Assets (ROA) | -52.70 | -15.80 | -9.38 | -9.13 | -10.35 | -11.11 | -25.06 | 1.34 | |
| Return on Equity (ROE) | -397.92 | -16.01 | -9.62 | -9.41 | -11.01 | -11.72 | -26.80 | 1.40 | |
| Return on Invested Capital (ROIC) | -53.61 | -9.65 | -10.52 | -10.71 | -10.87 | -11.35 | -27.34 | -10.48 | |
| Solvency | |||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 84.46 | - - | - - | 1.56 | 3.71 | 1.28 | 1.60 | 0.99 | |
| Debt/Equity | 637.72 | - - | - - | 1.61 | 3.95 | 1.35 | 1.71 | 1.04 | |
| Debt/EBITDA | 7.01 | 1,044.24 | 880.43 | 863.70 | 824.20 | 510.22 | 137.91 | 379.78 | |
|
Debt/Capitalization
|
86.44 | - - | - - | 1.58 | 3.80 | 1.33 | 1.68 | 1.03 | |
| Long-Term Debt/Capitalization | 86.44 | - - | - - | 1.35 | 1.12 | 1.16 | 1.39 | 0.84 | |
| Interest Debt per Share USD | 0.43 | 0.59 | 0.09 | 0.21 | 0.61 | 0.43 | 0.56 | 0.30 | |
| Debt Growth | - - | -100.00 | - - | - - | 253.96 | -30.50 | 11.33 | -9.39 | |
| Liquidity | |||||||||
| Current Ratio | 5,044.19 | 7,799.06 | 4,339.37 | 5,887.59 | 1,780.08 | 1,718.48 | 1,330.39 | 1,776.48 | |
| Quick Ratio | 4,472.09 | 7,748.59 | 4,305.12 | 5,821.61 | 1,755.51 | 1,702.27 | 1,314.42 | 1,735.11 | |
| Cash Ratio | 4,472.09 | 7,748.59 | 3,993.45 | 5,636.13 | 1,736.14 | 1,325.95 | 561.24 | 1,082.76 | |
| Operating Cash Flow Ratio | -3,000 | -600 | -300 | -500 | -100 | -100 | -300 | -200 | |
| Turnover | |||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | 115.98 | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | - - | 120.60 | |
| Payables Turnover | - - | - - | - - | 134.53 | 87.93 | 32.97 | 101.86 | 196.06 | |
|
Asset Turnover
|
- - | - - | 0.88 | - - | - - | - - | - - | 6.20 | |
| Fixed Turnover | - - | - - | 34.07 | - - | - - | - - | - - | 30.14 | |
| Coverage | |||||||||
| Interest Coverage | -16,328.57 | -151.59 | -1,160.27 | - - | - - | -4,576.07 | -2,781.00 | - - | |
| Asset Coverage | 100 | - - | - - | 6,300 | 2,600 | 7,400 | 5,900 | 9,700 | |
| Cash Flow Coverage (CFGR) | -71.13 | - - | - - | -573.67 | -225.91 | -597.43 | -1,125.81 | -1,097.16 | |
| EBITDA Coverage | -16,300 | -100 | -1,100 | - - | - - | -4,300 | -2,100 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -2.53 | -14.04 | -4.68 | -2.17 | -2.85 | -4.48 | -6.93 | 0.33 | |
|
Price/Earnings (P/E)
|
-3,955.73 | -712.03 | -2,137.94 | -4,613.38 | -3,504.30 | -2,231.81 | -1,442.72 | 30,815.48 | |
| Price/Earnings Growth (PEG) | - - | -1.59 | 62.04 | -194.56 | -82.45 | -26.88 | -19.13 | -287.23 | |
|
Price/Book (P/B)
|
15,740.78 | 113.98 | 205.61 | 433.98 | 385.93 | 261.58 | 386.70 | 432.64 | |
| Price/Tangible Book (P/TB) | 15,740.78 | 113.98 | 205.61 | 433.98 | 385.93 | 261.58 | 386.70 | 432.64 | |
| Price/Sales (P/S) | - - | - - | 22,667.97 | - - | - - | - - | - - | 6,644.61 | |
|
Price/Cash Flow (P/CF)
|
-3,469.93 | -1,449.69 | -2,464.80 | -4,705.83 | -4,321.70 | -3,238.91 | -2,008.03 | -3,793.47 | |
| Price/Free CF (P/FCF) | -3,430.68 | -1,375.44 | -1,993.32 | -3,506.70 | -2,754.31 | -1,335.35 | -1,315.19 | -3,348.56 | |
| Price/Operating CF (P/OCF) | -3,469.93 | -1,449.69 | -2,464.80 | -4,705.83 | -4,321.70 | -3,238.91 | -2,008.03 | -3,793.47 |